Eunice Wang, MD, shares the potential impact of gilteritinib as maintenance therapy after allogenic hematopoietic stem cell transplantation in patients with FLT3-ITD acute myeloid leukemia (AML)
The potential impact of gilteritinib in patients with FLT3-ITD AML?
